,133 Although the correlation between GPER and HER2-activating mutations remains unknown, we infer that simultaneous targeting of ER and HER2 might not be sufficient for the classical triple-positive (ER+/PR+/HER2+) BC. The gene discussed is ERBB2; the disease is breast cancer.